Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
CALGARY, Alberta, June 22, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study …